BAFF: a local and systemic target in autoimmune diseases

Area of Science:

• Immunology
• Autoimmunity
• Cytokine signaling

Background:

• B-cell activating factor (BAFF) is a key cytokine for B cell homeostasis and immune regulation.
• Elevated BAFF levels are observed in autoimmune diseases and sites of lymphoid neogenesis.
• BAFF blockade has shown promise in preclinical models of autoimmunity.

Purpose of the Study:

• To investigate the role of BAFF in autoimmune pathogenesis and the therapeutic potential of BAFF antagonism.
• To elucidate the mechanisms by which BAFF blockade impacts immune cells and inflammatory processes.

Main Methods:

• Studies involved BAFF antagonism in animal models of autoimmune diseases.
• Analysis of B cell populations, T cell and dendritic cell activation, and inflammatory markers.
• Investigation of BAFF and APRIL interactions with their receptors (BAFF-R, TACI, BCMA).

Main Results:

• BAFF blockade led to B cell depletion, reduced T cell and dendritic cell activation, and decreased inflammation in autoimmune models.
• BAFF is essential for the survival of transitional, marginal zone, and mature naive B cells.
• Blockade of BAFF and APRIL reduced IgG levels, indicating an impact on plasma cell survival.

Conclusions:

• BAFF antagonism is a promising therapeutic strategy for autoimmune diseases.
• The efficacy of BAFF blockade may stem from reduced inflammatory cell numbers and inhibited dendritic cell maturation.
• Clinical trials are underway to evaluate BAFF inhibitors for human autoimmune conditions.